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1. Introduction 
Glaziovianin A (1), isolated from the leaves of the Brazilian 
tree Ateleia glazioviana, exhibited a broad spectrum of 
cytotoxicity against a panel of 39 human cancer cell lines (termed 
JFCR39) at the Japanese Foundation for Cancer Research (Figure 
1).1 On the basis of COMPARE analysis, the pattern of the 
differential cytotoxicities of glaziovianin A (1) suggested that 
glaziovianin A (1) inhibits cancer cell proliferation by inhibiting 
tubulin polymerization.2 Indeed, we previously reported that 
glaziovianin A (1) arrested the cell cycle progression in M phase 
as do tubulin inhibitors.1 Interestingly, glaziovianin A (1) 
induced abnormal spindle structures with unaligned 
chromosomes  in mitotic cells, but did not influence on the 
microtubule network in interphase cells. Although the target 
molecule(s) or inhibitory mechanism remained to be revealed, 
these results suggest that glaziovianin A (1) is a novel mitotic 
inhibitor. Mitotic inhibitors including tubulin polymerization 
inhibitors have become clinically important drugs, especially 
against breast cancer.3 Also, glaziovianin A (1) showed antitumor 
activities in a mouse xenograft model (unpublished data). These 
results encouraged us to develop novel anticancer drugs based on 
glaziovianin A (1). A structure–cytotoxicity relationship study of 
glaziovianin A (1) was preliminarily reported by our group.4 In 
the present paper, we describe in detail the structure–activity 
relationships of glaziovianin A, specifically concerning its 
cytotoxicity and its effects on cell cycle progression and spindle 
structure. We also describe the synthesis of molecular probes of 
glaziovianin A for biological studies and target identification. 
 
 
 
 
 
 
 
Figure 1. Structure of glaziovianin A (1). 
 
We previously synthesized glaziovianin A (1) by using 
Suzuki–Miyaura coupling as a key step (Scheme 1).5 We used a 
similar strategy to synthesize glaziovianin A analogues. To 
develop these analogues, the structure of glaziovianin A (1) can 
be divided into two structural moieties: an A-ring and a B-ring 
(Figure 2). Therefore, we synthesized 3-iodochromone analogues 
as an A-ring and boron compounds as a B-ring. 
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Scheme 1. Total synthesis of glaziovianin A (1) by our group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Key structural moieties of glaziovianin A. 
 
2. Results and discussion 
2.1. Synthesis of B-ring analogues of glaziovianin A 
First, we prepared B-ring analogues of glaziovianin A 
(Scheme 2). The diol group in 3,6-dimethoxybenzene-1,2-diol 
(6)6 was protected as an acetonide group to give compound 7. 
The bromination of 7 gave a monobromo compound, which was 
converted into arylboronate 8 by using PdCl2(dppf), 
bis(pinacolato)diboron, and KOAc in DMF at 150 °C.7 The 
Suzuki–Miyaura coupling8 between 3-iodo-6,7-dimethoxy-4H-
chromen-4-one (3)5 and boron compounds, such as arylboronate 
8, 2,3,4,5-tetramethoxyphenylboronic acid (10),9 or 
commercially available 3,4-(methylenedioxy)phenylboronic acid 
(11), gave glaziovianin A analogues 12–14, respectively. On the 
other hand, bromide 15 was synthesized from selective 
bromination at the C6’ position of glaziovianin A (1). 
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Scheme 2. Synthesis of B-ring analogues of glaziovianin A. 
Reagents and conditions: (a) 2-methoxypropene, PPTS, 
benzene, reflux, 72%; (b) NBS, DMF, rt, 57%; (c) 
bis(pinacolato)diboron, PdCl2(dppf), KOAc, DMF, 150 °C, 
28%; (d) n-BuLi, B(OMe)3, THF, rt; (e) 3, PdCl2(dppf), 1 M 
Na2CO3 aq., 1,4-dioxane, rt {64% for 12, 11% for 13 (from 9), 
41% for 14}; (f) NBS, DMF, rt, 31%. 
 
2.2. Synthesis of A-ring analogues of glaziovianin A 
Next, we tried to modify the A-ring part of glaziovianin A 
(Scheme 3). The hydroxy group at the C7 position of 1610 was 
protected as a THP group to afford compound 17. Condensation 
of 17 with N,N-dimethylformamide dimethyl acetal gave an 
enamine in quantitative yield. Iodinative cyclization of the 
enamine afforded iodochromone 18.11 The cross coupling 
reaction of arylboronate 55 and iodochromone compounds 18 
and 1912, gave glaziovianin A analogues 20 and 21, respectively. 
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Scheme 3. Synthesis of glaziovianin A analogues 20 and 21. 
Reagents and conditions: (a) DHP, PPTS, CH2Cl2, rt, 80%; 
(b) Me2NCH(OMe)2, 90 °C, quant; (c) I2, py, CHCl3, rt, 75%; 
(d) 5, PdCl2(dppf), 1 M Na2CO3 aq., 1,4-dioxane, rt (66% for 
20, 16% for 21) 
 
Next, we attempted to synthesize glaziovianin A analogues 
that have various functional groups at the C7 position (Scheme 4). 
Treatment of compound 20 with p-TsOH·H2O provided O7-
demethyl analogue 22, which is a suitable precursor for the 
synthesis of O7-modified glaziovianin A. Thus, we tried to 
synthesize glycoside 25 and diol 27 in order to improve water 
solubility. Glycosylation of the O7 position in 22 with tetraacetyl 
glucopyranosyl trichloroacetimidate 23 by using Schmidt 
glycosylation13 gave tetraacetyl glycosylisoflavone 24. Removal 
of the acetyl groups of 24 by using NaOMe afforded glycoside 
25. Next, allylation of O7-demethyl analogue 22 with allyl 
bromide gave allyl ether 26. Dihydroxylation of the terminal 
olefin of 26 afforded diol 27. On the other hand, the hydroxy 
group at the C7 position in 22 was alkylated into benzyl ether 28 
and propargyl ether 29 in order to increase lipid solubility. 
 
Scheme 4. Synthesis of O7-modified analogues of 
glaziovianin A. Reagents and conditions: (a) p-TsOH·H2O, 
MeOH, CHCl3, rt, 85%; (b) 23, BF3·Et2O, MS3A, CH2Cl2, rt, 
27% (:  = 1 : 5.6); (c) NaOMe, MeOH, rt, 91%; (d) allyl 
bromide, K2CO3, MeCN, rt, 81%; (e) OsO4, py, rt, 84%; (f) 
benzyl bromide, K2CO3, MeCN, rt, 80%; (g) propargyl 
bromide, K2CO3, MeCN, rt, 67%. 
 
2.3. Cytotoxicity of glaziovianin A (1) and its analogues 
against HeLa S3 cells 
Table 1 summarizes the cytotoxicity of glaziovianin A (1) and 
its analogues against HeLa S3 cells and their calculated Log P 
(cLog P) values.14 Compound 12, which has an acetonide group 
instead of the methylene acetal group of glaziovianin A (1), 
showed no cytotoxicity even at 100 M. Also, compound 13, 
which has methoxy groups at C3’ and C4’ instead of the 
methylene acetal group, was much less cytotoxic than 
glaziovianin A (1). These results indicated that the steric 
hindrance of C3’ and C4’ at the B-ring part reduced the 
cytotoxicity of glaziovianin A (1) to a large extent. Compound 14, 
which lacks methoxy groups at C2’ and C5’, was about 100-fold 
less cytotoxic than glaziovianin A (1). Also, compound 15, which 
has a bromo group at C6’ of the B-ring, was less cytotoxic than 
glaziovianin A (1). These results suggested that the electron 
density and/or steric hindrance of the B-ring might be responsible 
for cytotoxicity. On the other hand, compound 21, which has an 
extra methoxy group at C5 of the A-ring, showed no cytotoxicity 
even at 100 M, indicating that the steric hindrance and electron 
density of the A-ring extinguished cytotoxicity. O7-Demethyl 
analogue 22 exhibited no cytotoxicity, perhaps because of its 
instability. On the other hand, compounds 24, 25, and 27, which 
have O7-hydrophilic functional groups, showed no cytotoxicity at 
100 M, and the cLog P values of these compounds, 1.00, 0.08, 
and 1.13, are much smaller than that of glaziovianin A (1). These 
results showed that the improvement of water solubility 
diminishes cytotoxicity. In contrast, compounds 26, 28, and 29, 
which have, respectively, an allyl, a benzyl, and a propargyl 
group at O7 instead of the methyl group, showed cytotoxicity 
with IC50 values of 0.46, 0.19, and 0.17 M, respectively.15 Thus, 
some alkyl groups at O7 had enhanced cytotoxicity against HeLa 
S3 cells. In particular, O7-propargyl analogue 29 is more active 
than glaziovianin A (1) itself. These results indicated that the 
hydrophobicity of the O7-alkyl group in glaziovianin A analogues 
improves cytotoxicity. However, compound 20, which has a THP 
group at O7, showed no cytotoxicity even at 100 M. This 
indicated that steric hindrance of the O7-substituent reduces 
cytotoxicity to a large extent. 
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Table 1 Cytotoxicity of glaziovianin A (1) and its analogues 
against HeLa S3 cells 
  cytotoxicity 
compound cLog P IC50 (M) relative value
glaziovianin A (1) 2.19 0.59 1   
12 2.79 >100 - 
13 2.15 22.0 0.027 
14 2.44 56.2 0.010 
15 3.02 67.8 0.009 
20 3.03 >100 - 
21 2.06 >100 - 
22 1.92 >100 - 
24 1.00 >100 - 
25 0.08 >100 - 
26 2.88 0.46 1.3 
27 1.13 >100 - 
28 3.92 0.19 3.1 
29 2.40 0.17 3.5 
 
2.4. Effects of glaziovianin A (1) and O7-alkylated analogues 
26, 28, and 29 on cell cycle progression and spindle structures 
in HeLa S3 cells 
We previously reported that glaziovianin A (1) inhibited the 
cell cycle progression in the M-phase with abnormal spindle 
structures.1 Here, we investigated the effects of the cytotoxic O7-
alkylated analogues 26, 28, and 29 on both cell cycle progression 
and spindle structures.16,17 As shown in Figures 3A–E, all the 
analogues inhibited the cell cycle progression in the G2/M phase 
at a concentration of 1 μM for 24 h treatment. To confirm 
whether or not these compounds also induce abnormal spindle 
structures with unaligned chromosomes, as does 1, microtubules 
and chromosomes in mitotic cells treated with 1 μM O7-alkylated 
analogues for 6 h were observed (Figures 3F–J). Normal bipolar 
spindles were observed in DMSO-treated cells, but abnormal 
multipolar spindles were formed in most of the cells treated with 
1 (Figures 3F and 3G, respectively). As expected, analogues 26, 
28, and 29 also induced abnormal multipolar spindles, and these 
structures were resembled with the spindles induced by 1 
(Figures 3H–J). Because it is well known that the disruption of a 
mitotic spindle inhibits mitosis by activating the spindle 
checkpoint, these results strongly suggested that O7-alkylated 
analogues inhibited cell cycle progression in the M phase by 
inducing abnormal spindle formation. Especially, benzyl (28) and 
propargyl (29) analogues completely arrested cell cycle 
progression, indicating that these compounds are more potent cell 
cycle inhibitors than 1 and 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effects of glaziovianin A (1) and O7-alkylated analogues 26, 28, and 29 on cell cycle progression and spindle structures in HeLa S3 cells.  
(A–E) O7-alkylated analogues inhibited cell cycle progression in G2/M phase. HeLa S3 cells were treated with DMSO (A), 1 μM of glaziovianin A (1) (B), 
compound 26 (C), 28 (D), or 29 (E) for 24 h, and DNA contents were determined with flow cytometric analysis.  
(F–J) O7-alkylated analogues induced abnormal spindle formation. HeLa S3 cells were treated with DMSO (F), 1 μM of glaziovianin A (1) (G), compound 26 
(H), 28 (I), or 29 (J) for 6 h, and microtubules (green) and chromosomes (blue) were stained with anti-α-tubulin antibody (DM1A, Santa Cruz Biotechnology) 
and DAPI, respectively.
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2.5 Synthesis of biotin, fluorescence, and photoaffinity probes 
of glaziovianin A 
In section 2.3, we described that O7-alkylated glaziovianin A 
analogues showed more potent cytotoxicity against HeLa S3 cells 
than glaziovianin A itself. So, we next examined the synthesis of 
O7-modified molecular probes of glaziovianin A for biological 
studies and target identification. First, we synthesized a biotin 
probe of glaziovianin A (1) to confirm the target biomolecule, 
tubulin (Scheme 5). Condensation of mono-Boc-1,6-
diaminohexane 3018 with 6-benzyloxyhexanoic acid 3119 gave 
amide 32. Removal of the benzyl group of 32 afforded an alcohol, 
which was converted into bromide 33. The coupling reaction 
between bromide 33 and O7-demethyl analogue 22, followed by 
removal of the Boc group gave amine 34 as a TFA salt. 
Amidation of amine 34 with (+)-biotin N-hydroxysuccinimide 
ester 3520 afforded O7-biotinyl glaziovianin A (36). 
 
Scheme 5. Synthesis of biotin probe of glaziovianin A. 
Reagents and conditions: (a) DCC, HOBt, DMF, rt, 81%; (b) 
H2, 5% Pd/C, EtOH, rt, 89%; (c) NBS, PPh3, CH2Cl2, rt, 40%; 
(d) 22, K2CO3, MeCN, reflux, 34%, recovery of 22: 46%; (e) 
TFA, CH2Cl2, rt, 62%; (f) 35, Et3N, DMF, rt, 41%. 
 
Next, we synthesized a fluorescent probe for a dynamic 
analysis of glaziovianin A in living cells, as well as a 
photoaffinity probe for an analysis of the binding site between 
glaziovianin A and the target protein. In Scheme 5, the coupling 
reaction between bromide 33 and O7-demethyl analogue 22 was 
in low yield, perhaps because of the low reactivity of bromide 33. 
Therefore, we next tried to employ allylic bromide 42 as a linker 
(Scheme 6). Reduction of known aldehyde 3721 gave allylic 
alcohol 38, which was protected by a TBS group, thus affording 
TBS ether 39. Condensation of TBS ether 39 and amine 30 gave 
amide 40. Removal of the TBS group in 40 afforded allylic 
alcohol 41, which was converted into allylic bromide 42. The 
coupling reaction between O7-demethyl analogue 22 and allylic 
bromide 42 gave the coupling compound 43 in good (72%) yield. 
Removal of the Boc group in coupling compound 43 gave amine 
44 as a TFA salt. Amidation of compound 44 with N-
hydroxysuccinimide esters, such as (+)-biotin analogue 35,20 
trifluoromethyldiazirine analogue 48,22 and BODIPY analogue 
49,23 afforded O7-modified biotin probe 45, photoaffinity probe 
46, and fluorescent probe 47, respectively. 
 
Scheme 6. Synthesis of biotin, photoaffinity, and fluorescent 
probes of glaziovianin A. Reagents and conditions: (a) NaBH4, 
MeOH, 0 °C, 70%; (b) TBSCl, imidazole, DMF, rt, 91%; (c) 
30, toluene, reflux, 69%; (d) TBAF, THF, rt, 86%; (e) NBS, 
PPh3, CH2Cl2, rt, 64%; (f) 22, K2CO3, MeCN, reflux, 72%, 
recovery of 22: 14%; (g) TFA, CH2Cl2, rt, 55%; (h) 35, Et3N, 
DMF, rt, 47% (i) 48, Et3N, MeCN, rt, 49%; (j) 49, Et3N, DMF, 
rt, 65%. 
 
The cytotoxicities of biotin probes 36 and 45, as well as that 
of fluorescent probe 47, against HeLa S3 cells are shown in Table 
2. Each of these probes was about 30-fold less cytotoxic than 
glaziovianin A (1). However, they all maintained sufficient 
cytotoxicities to be used as probes. 
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Table 2 Cytotoxicities of glaziovianin A (1) and the 
molecular probes of glaziovianin A against HeLa S3 cells 
 cytotoxicity 
compound IC50 (M) relative value 
glaziovianin A (1) 0.59 1 
biotin probe 36 15.2 0.039 
biotin probe 45 15.5 0.038 
BODIPY probe 47 17.4 0.034 
 
3. Conclusion 
In conclusion, we have investigated the structure–cytotoxicity 
relationships of glaziovianin A (1). The results revealed that O7-
modified glaziovianin A analogues have strong cytotoxicity 
against HeLa S3 cells. Among them, O7-benzyl and O7-propargyl 
analogues 28 and 29 completely arrested cell cycle progression, 
indicating that these compounds are more potent cell cycle 
inhibitors than glaziovianin A (1). Furthermore, we have 
synthesized O7-modified molecular probes of glaziovianin A for 
biological studies. Further searches for target biomolecules of 
glaziovianin A (1) by using these probes are in progress. 
 
4. Experimental section 
4.1. Chemistry 
General method 
1H NMR spectra were recorded on a JEOL JNM-EX270 (270 
MHz) or a Bruker AVANCE 500 (500 MHz) spectrometer. 
Chemical shifts for 1H NMR are reported in parts per million 
(ppm) downfield from tetramethylsilane as the internal standard, 
and coupling constants are in hertz (Hz). The following 
abbreviations are used for spin multiplicity: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, and br = broad. 13C 
NMR spectra were recorded on a JEOL JNM-EX270 (67.8 MHz) 
or a Bruker AVANCE 500 (125 MHz) spectrometer. Chemical 
shifts for 13C NMR are reported in ppm, relative to the central 
line of a triplet at 77.0 ppm for deuteriochloroform. IR spectra 
were recorded on a JASCO FT/IR-300 instrument and are 
reported in wavenumbers (cm−1). High resolution ESI mass 
spectra were recorded on an Applied Biosystems QStar/Pulsar i 
spectrometer. Fuji Silysia silica gel BW-820MH was used for 
column chromatography. Anhydrous benzene, CH2Cl2, MeOH, 
THF, toluene, and MeCN were used as obtained from 
commercial supplies for moisture-sensitive reaction. Other 
organic solvents for moisture-sensitive reactions were distilled by 
standard procedure. MS3A was heated in a microwave oven for 2 
minutes. 
 
4.1.1.  4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxole (7) 
To a stirred solution of catechol 6 (54.3 mg, 319 mol) in 
benzene (2.5 mL) were added PPTS (5.5 mg, 21.9 mol) and 2-
methoxypropene (0.10 mL, 1.04 mmol) at room temperature. 
After being stirred at reflux for 48 h, the mixture was cooled to 
room temperature, diluted with EtOAc (5 mL), and washed with 
1 M aqueous NaOH (3 mL). The EtOAc solution was washed 
with brine (3 mL), dried (Na2SO4), and concentrated. The 
residual solid was purified by column chromatography on silica 
gel (0.8 g, hexane–EtOAc = 40:1) to give acetonide 7 (48.6 mg, 
72%) as a white solid: IR (CHCl3) 3024, 2987, 2941, 1612, 1450, 
1423, 1055 cm−1; 1H NMR (270 MHz, CDCl3) δ 6.40 (s, 2H), 
3.84 (s, 6H), 1.73 (s, 6H); 13C NMR (67.8 MHz, CDCl3) δ 120.5 
(2C), 118.6 (2C), 117.0 (2C), 106.5, 60.1 (2C), 20.9 (2C); HRMS 
(ESI) m/z 233.0772, calcd for C11H14NaO4 [M+Na]+ 233.0784. 
 
4.1.2.  5-Bromo-4,7-dimethoxy-2,2-
dimethylbenzo[d][1,3]dioxole (7a) 
To a stirred solution of acetonide 7 (48.6 mg, 231 mol) in 
DMF (2.6 mL) was added NBS (34.9 mg, 196 mol) at 0 °C. 
After being stirred at room temperature for 18 h in dark, the 
mixture was diluted with water (3 mL) and extracted with CH2Cl2 
(2 mL×3). The combined extracts were washed with brine (5 mL), 
dried (Na2SO4), and concentrated. The residual solid was purified 
by column chromatography on silica gel (2.0 g, hexane–CH2Cl2 = 
8:1) to give bromide 7a (38.2 mg, 57%) as a white solid: IR 
(CHCl3) 3007, 2992, 2941, 1610, 1453, 1430, 1412, 1045, 1026 
cm−1; 1H NMR (270 MHz, CDCl3) δ 6.64 (s, 1H), 3.89 (s, 3H), 
3.83 (s, 3H), 1.72 (s, 6H); 13C NMR (67.8 MHz, CDCl3) δ 131.2, 
130.7, 128.1, 126.9, 126.4, 115.2, 105.8, 61.5, 59.7, 21.3, 21.2; 
HRMS (ESI) m/z 310.9899, calcd for C11H13BrNaO4 [M+Na]+ 
310.9889. 
 
4.1.3.  2-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-
yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8) 
To a stirred solution of bis(pinacolato)diboron (52.5 mg, 207 
mol), PdCl2(dppf)·CH2Cl2 (11.3 mg, 13.8 mol), and KOAc 
(54.5 mg, 556 mol) in DMF (0.60 mL) was added a solution of 
bromide 7a (39.7 mg, 138 mol) in DMF (0.50 mL) at room 
temperature. After being stirred at 150 °C under a stream of N2 
for 3 h, the mixture was cooled to room temperature, diluted with 
EtOAc (4 mL), and washed with brine (2 mL). The EtOAc 
solution was dried (Na2SO4), filtered through a pad of Florisil, 
and concentrated. The residual oil was purified by column 
chromatography on silica gel (0.8 g, hexane–EtOAc = 100:1 → 
20:1) to give arylboronate 8 (12.9 mg, 28%) as a white solid: IR 
(CHCl3) 3010, 2987, 2941, 1608, 1452, 1435, 1302, 1058 cm−1; 
1H NMR (270 MHz, CDCl3) δ 6.81 (s, 1H), 3.87 (s, 3H), 3.84 (s, 
3H), 1.70 (s, 6H), 1.33 (s, 12H); 13C NMR (67.8 MHz, CDCl3) δ 
142.9, 142.5, 139.1, 138.8, 137.7, 114.0, 106.6, 83.1 (2C), 61.4, 
57.2, 25.0 (4C), 21.6, 21.4; HRMS (ESI) m/z 359.1646, calcd for 
C17H25BNaO6 [M+Na]+ 359.1636. 
 
4.1.4.  3-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-
yl)-6,7-dimethoxy-4H-chromen-4-one (12) 
All solvents were degassed by freeze–thawing. To a stirred 
solution of arylboronate 8 (12.9 mg, 38.4 mol) and 
PdCl2(dppf)·CH2Cl2 (3.1 mg, 3.79 mol) in 1,4-dioxane (0.25 
mL) were added aqueous 1 M Na2CO3 (0.19 mL, 190 mol) and 
iodochromone 3 (19.1 mg, 57.5 mol) in 1,4-dioxane (0.30 mL) 
at room temperature. After being stirred at room temperature 
under a stream of N2 for 36 h, the mixture was diluted with 
EtOAc (2 mL) and filtered through a pad of Florisil. The filtrate 
was washed with brine (4 mL), dried (Na2SO4), and concentrated. 
The residual solid was purified by column chromatography on 
silica gel (0.6 g, hexane–EtOAc = 10:1 → 1:1) to give a brown 
solid (containing Pd-metal) (10.1 mg, 64%). The brown solid 
(10.1 mg) was dissolved in CHCl3 (1 mL), and SiliaBond 
(SILICYCLE, SiliaBond Thiourea, 100 mg) was added. The 
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resulting mixture was stirred at room temperature for 30 min, 
filtered, and concentrated to give glaziovianin A analogue 12 
(10.1 mg, 64%) as a white solid: IR (CHCl3) 3016, 2937, 1634, 
1605, 1444, 1278, 1160, 1037 cm−1; 1H NMR (270 MHz, CDCl3) 
δ 7.92 (s, 1H), 7.62 (s, 1H), 6.87 (s, 1H), 6.49 (s, 1H), 3.99 (s, 
3H), 3.98 (s, 3H), 3.88 (s, 3H), 3.85 (s, 3H), 1.67 (s, 3H), 1.65 (s, 
3H); 13C NMR (67.8 MHz, CDCl3) δ 175.5, 154.0, 153.2, 152.1, 
147.4, 139.0, 138.5, 137.0, 136.5, 121.5, 117.9, 117.7, 110.3, 
106.4, 104.7, 99.4, 60.2, 56.9, 56.2, 56.0, 20.9, 20.7; HRMS 
(ESI) m/z 437.1213, calcd for C22H22NaO8 [M+Na]+ 437.1207. 
 
4.1.5.  2,3,4,5-Tetramethoxyphenylboronic acid (10) 
To a stirred solution of tetramethoxybenzene 9 (101 mg, 510 
mol) in THF (1.0 mL) was added n-BuLi (1.63 M solution in 
hexane, 0.34 mL, 554 mol) slowly at room temperature. After 
the mixture was stirred at room temperature for 15 min, B(OMe)3 
(0.34 mL, 2.99 mmol) was added into the mixture at –78 °C. The 
reaction mixture was stirred at room temperature for 3 h, diluted 
with aqueous 1 M HCl (2.5 mL), stirred at room temperature for 
3 h, and extracted with ether (2 mL×3). The combined extracts 
were washed with brine (5 mL) and dried (MgSO4). Removal of 
the solvent afforded boronic acid 10 (138 mg) as a white solid, 
which was used for the next reaction without further purification. 
 
4.1.6.  6,7-Dimethoxy-3-(2,3,4,5-tetramethoxyphenyl)-4H-
chromen-4-one (13) 
To a stirred solution of crude boronic acid 10 (41.0 mg, 152 
mol) and PdCl2(dppf)·CH2Cl2 (17.8 mg, 15.4 mol) in 1,4-
dioxane (1.0 mL) were added 1 M Na2CO3 aq. (0.75 mL, 750 mol) and iodochromone 3 (103 mg, 310 mol) in 1,4-dioxane 
(1.0 mL) at room temperature. After being stirred at room 
temperature under a stream of N2 for 17 h, the reaction mixture 
was diluted with water (1 mL) and extracted with CH2Cl2 (2 
mL×3). The combined extracts were washed with brine (3 mL), 
dried (Na2SO4), filtered through a pad of Florisil, and 
concentrated. The residual oil was purified by column 
chromatography on silica gel (3.0 g, hexane–EtOAc = 4:1 → 2:1) 
to give a brown solid (containing Pd-metal) (7.0 mg). The brown 
solid (7.0 mg) was dissolved in CHCl3 (1 mL), and SiliaBond 
(SILICYCLE, SiliaBond Thiourea, 70 mg) was added. The 
resulting mixture was stirred at room temperature for 30 min, 
filtered, and concentrated to give glaziovianin A analogue 13 (7.0 
mg, 11% in 2 steps) as a white solid: IR (CHCl3) 3010, 2946, 
1637, 1606, 1448, 1297, 1271, 1072 cm−1; 1H NMR (270 MHz, 
CDCl3) δ 7.92 (s, 1H), 7.62 (s, 1H), 6.88 (s, 1H), 6.67 (s, 1H), 
4.00 (s, 3H), 3.98 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.87 (s, 3H), 
3.86 (s, 3H); 13C NMR (67.8 MHz, CDCl3) δ 175.0, 154.4, 153.3, 
152.0, 147.4, 139.9, 139.3, 137.8, 137.4, 121.5, 119.0, 117.7, 
110.6, 104.8, 99.7, 60.8, 58.7, 57.4, 57.1, 56.4, 56.2; HRMS 
(ESI) m/z 425.1201, calcd for C21H22NaO8 [M+Na]+ 425.1207. 
 
4.1.7.  3-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4H-
chromen-4-one (14) 
To a stirred solution of boronic acid 11 (50.4 mg, 152 mol) 
and PdCl2(dppf)·CH2Cl2 (17.1 mg, 14.8 mol) in 1,4-dioxane 
(1.0 mL) were added 1 M Na2CO3 aq. (0.75 mL, 750 mol) and 
iodochromone 3 (108 mg, 323 mol) in 1,4-dioxane (1.0 mL) at 
room temperature. After being stirred at room temperature under 
a stream of N2 for 12 h, the reaction mixture was diluted with 
water (1 mL) and extracted with CH2Cl2 (2 mL×3). The 
combined extracts were washed with brine (3 mL), dried 
(Na2SO4), filtered through a pad of Florisil, and concentrated. 
The residual oil was purified by column chromatography on 
silica gel (0.7 g, hexane–CHCl3 = 1:1 → 1:2) to give a brown 
solid (containing Pd-metal) (21.0 mg). The brown solid (21.0 
mg) was dissolved in CHCl3 (3 mL), and SiliaBond (SILICYCLE, 
SiliaBond Thiourea, 200 mg) was added. The resulting mixture 
was stirred at room temperature for 30 min, filtered, and 
concentrated to give a glaziovianin A analogue 14 (20.2 mg, 
41%) as a white solid: IR (CHCl3) 3005, 2940, 1635, 1608, 1439, 
1274, 1154 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.92 (s, 1H), 
7.62 (s, 1H), 7.11 (d, J = 1.9 Hz, 1H), 6.98 (dd, J = 8.1, 1.9 Hz, 
1H), 6.88 (s, 1H), 6.87 (d, J = 8.1 Hz, 1H), 5.99 (s, 2H), 3.99 (s, 
3H), 3.99 (s, 3H); 13C NMR (67.8 MHz, CDCl3) δ 175.2, 154.1, 
153.1, 152.2, 147.6, 143.0, 142.2, 139.9, 139.0, 121.8, 121.6, 
117.6, 113.8, 104.9, 101.8, 99.7, 56.5, 56.3; HRMS (ESI) m/z 
349.0683, calcd for C18H14NaO6 [M+Na]+ 349.0683. 
 
4.1.8.  3-(6-Bromo-4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-
6,7-dimethoxy-4H-chromen-4-one (15) 
To a stirred solution of glaziovianin A (1) (10.2 mg, 26.4 
mol) in DMF (0.25 mL) was added NBS (4.7 mg, 26.6 mol) at 
room temperature. After being stirred at room temperature for 6 h, 
the reaction mixture was diluted with water (0.5 mL) and 
extracted with CH2Cl2 (1 mL×3). The combined extracts were 
washed with brine (2 mL), dried (Na2SO4), and concentrated. The 
residual oil was purified by column chromatography on silica gel 
(0.7 g, hexane–EtOAc = 5:1 → 2:1) to give a bromide 15 (3.8 mg, 
31%) as a white solid: IR (CHCl3) 3004, 2937, 1640, 1612, 1505, 
1428, 1264, 1155, 1047 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.75 
(s, 1H), 7.62 (s, 1H), 6.92 (s, 1H), 6.03 (s, 2H), 4.00 (s, 3H), 3.99 
(s, 3H), 3.85 (s, 3H), 3.83 (s, 3H); 13C NMR (67.8 MHz, CDCl3) δ 175.2, 154.2, 153.3, 152.0, 147.2, 139.1, 138.7, 137.2, 136.5, 
121.6, 118.3, 117.6, 104.9, 101.8, 99.5, 86.4, 60.5, 57.2, 56.4, 
56.2; HRMS (ESI) m/z 486.9985, calcd for C20H17BrNaO8 
[M+Na]+ 486.9999. 
 
4.1.9.  1-(2-Hydroxy-5-methoxy-4-(tetrahydro-2H-pyran-2-
yloxy)phenyl)ethanone (17) 
To a stirred solution of phenol 16 (16.5 mg, 90.7 mol) in 
CH2Cl2 (0.90 mL) were added DHP (102 L, 1.12 mol) and 
PPTS (3.2 mg, 12.7 mol) at 0 °C. After being stirred at room 
temperature for 18 h, the reaction mixture was diluted with 
saturated aqueous NaHCO3 (1 mL) and extracted with CH2Cl2 (2 
mL×3). The combined extracts were washed with brine (2 mL), 
dried (Na2SO4), and concentrated. The residual solid was purified 
by column chromatography on silica gel (1.5 g, hexane–EtOAc = 
20:1) to give THP ether 17 (19.3 mg, 80%) as a white solid: IR 
(CHCl3) 3518, 3014, 2950, 1632, 1504, 1372, 1330, 1261, 1228, 
1216, 1208 cm−1; 1H NMR (270 MHz, CDCl3) δ 12.5 (s, 1H), 
7.12 (s, 1H), 6.74 (s, 1H), 5.50 (t, J = 3.0 Hz, 1H), 3.89–3.82 (m, 
1H), 3.85 (s, 3H), 3.66–3.62 (m, 1H), 2.56 (s, 3H), 2.01–1.89 (m, 
3H), 1.74–1.64 (m, 3H); 13C NMR (67.8 MHz, CDCl3) δ 201.8, 
159.3, 154.2, 142.1, 113.3, 112.3, 104.3, 96.6, 62.1, 57.1, 29.9, 
26.2, 24.8, 18.5; HRMS (ESI) m/z 289.1051, calcd for 
C14H18NaO5 [M+Na]+ 289.1046. 
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4.1.10.  (E)-3-(Dimethylamino)-1-(2-hydroxy-5-methoxy-4-
(tetrahydro-2H-pyran-2-yloxy)phenyl)prop-2-en-1-one (17a) 
THP ether 17 (19.3 mg, 72.6 mol) was dissolved in N,N-
dimethylformamide dimethyl acetal (0.10 mL, 754 mol). The 
reaction mixture was stirred at 90 °C for 12 h and concentrated to 
afford enamine 17a (23.3 mg, quant.) as a yellow solid. Enamine 
17a was used for next reaction without further purification: IR 
(CHCl3) 3689, 2949, 1631, 1541, 1507, 1372, 1284, 1222, 1209, 
1108 cm−1; 1H NMR (270 MHz, CDCl3) δ 14.0 (s, 1H), 7.84 (d, J 
= 12.4 Hz, 1H), 7.18 (s, 1H), 6.72 (s, 1H), 5.62 (d, J = 12.4 Hz, 
1H), 5.46 (t, J = 3.2 Hz, 1 H), 3.89 (m, 1H), 3.85 (s, 3H), 3.63 (m, 
1H), 3.22 (br s, 3H), 3.17 (br s, 3H), 2.01–1.88 (m, 3H), 1.72–
1.61 (m, 3H); 13C NMR (67.8 MHz, CDCl3) δ 190.2, 160.0, 
154.0, 152.7, 141.7, 113.6, 112.9, 105.0, 96.8, 89.8, 62.4, 58.2, 
40.3 (2C), 30.2, 25.1, 19.0; HRMS (ESI) m/z 344.1471, calcd for 
C17H23NNaO5 [M+Na]+ 344.1474. 
 
4.1.11.  3-Iodo-6-methoxy-7-(tetrahydro-2H-pyran-2-yloxy)-
4H-chromen-4-one (18) 
To a stirred solution of enamine 17a (150 mg, 467 mol) in 
CHCl3 (4.7 mL) were added pyridine (0.19 mL, 2.36 mmol) and 
I2 (250 mg, 984 mol) at 0 °C. After being stirred at room 
temperature for 12 h in dark, the mixture was diluted with 
saturated aqueous Na2S2O3 (5 mL), stirred at room temperature 
for 10 min, and extracted with EtOAc (5 mL×3). The combined 
extracts were washed with brine (10 mL), dried (Na2SO4), and 
concentrated. The residual solid was purified by column 
chromatography on silica gel (8 g, hexane–EtOAc = 10:1 → 4:1) 
to give iodochromone 18 (140 mg, 75%) as a white solid: IR 
(CHCl3) 3024, 2999, 1640, 1605, 1541, 1503, 1350, 1219, 1203 
cm−1; 1H NMR (270 MHz, CDCl3) δ 8.22 (s, 1H), 7.55 (s, 1H), 
7.20 (s, 1H), 5.55 (t, J = 2.7 Hz, 1H), 3.95 (s, 3H), 3.91–3.82 (m, 
1H), 3.68–3.63 (m, 1H), 2.10–1.87 (m, 3H), 1.77–1.62 (m, 3H); 
13C NMR (67.8 MHz, CDCl3) δ 172.2, 156.8, 156.7, 151.7, 148.5, 
115.6, 105.2, 103.7, 97.1, 86.2, 62.0, 56.3, 29.9, 24.9, 18.3; 
HRMS (ESI) m/z 424.9867, calcd for C15H15INaO5 [M+Na]+ 
424.9862. 
 
4.1.12.  3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-
7-(tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (20) 
All solvents were degassed by freeze–thawing. To a stirred 
solution of arylboronate 5 (10.1 mg, 32.8 mol) and 
PdCl2(dppf)·CH2Cl2 (2.2 mg, 2.69 mol) in 1,4-dioxane (0.10 
mL) were added aqueous 1 M Na2CO3 (0.13 mL) and 
iodochromone 18 (10.4 mg, 25.9 mol) in 1,4-dioxane (0.22 mL) 
at room temperature. After being stirred at room temperature 
under a stream of N2 for 24 h, the reaction mixture was diluted 
with water (1 mL) and extracted with CH2Cl2 (1 mL×3). The 
combined extracts were washed with brine (2 mL), dried 
(Na2SO4), filtered through a pad of Florisil, and concentrated. 
The residual oil was purified by column chromatography on 
silica gel (0.7 g, hexane–EtOAc = 4:1 → 2:1) to give a brown oil 
(7.9 mg). The brown oil (7.9 mg) was dissolved in CHCl3 (1 mL), 
and SiliaBond (SILICYCLE, SiliaBond Thiourea, 80 mg) was 
added. The resulting mixture was stirred at room temperature for 
30 min, filtered, and concentrated to give a glaziovianin A 
analogue 20 (7.8 mg, 66%) as a white solid: IR (CHCl3) 3007, 
2948, 1639, 1607, 1500, 1468, 1430, 1352, 1297 cm−1; 1H NMR 
(270 MHz, CDCl3) δ 7.90 (s, 1H), 7.62 (s, 1H), 7.22 (s, 1H), 6.52 
(s, 1H), 6.01 (s, 2H), 5.56 (s, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.83 
(s, 3H), 2.06–1.97 (m, 4H), 1.72–1.68 (m, 4H); 13C NMR (67.8 
MHz, CDCl3) δ 175.4, 153.5, 151.8, 151.4, 148.2, 139.0, 138.8, 
136.9, 136.6, 121.3, 118.4, 118.0, 109.9, 105.3, 104.2, 101.9, 
97.1, 62.1, 60.2, 56.9, 56.4, 30.1, 25.1, 18.5; HRMS (ESI) m/z 
479.1310, calcd for C24H24NaO9 [M+Na]+ 479.1313. 
 
4.1.13.  3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-5,6,7-
trimethoxy-4H-chromen-4-one (21) 
All solvents were degassed by freeze–thawing. To a stirred 
solution of arylboronate 5 (20.6 mg, 66.9 mol) and 
PdCl2(dppf)·CH2Cl2 (5.8 mg, 7.10 mol) in 1,4-dioxane (0.45 
mL) were added aqueous 1 M Na2CO3 (0.32 mL, 320 mol) and 
iodochromone 19 (36.5 mg, 101 mol) in 1,4-dioxane (0.48 mL) 
at room temperature. After being stirred at room temperature 
under a stream of N2 for 48 h, the reaction mixture was diluted 
with EtOAc (2 mL) and filtered through a pad of Florisil. The 
filtrate was washed with brine (4 mL), dried (Na2SO4), and 
concentrated. The residual solid was purified by column 
chromatography on silica gel (1.5 g, hexane–EtOAc = 5:1 → 2:1) 
to give glaziovianin A analogue 21 (4.5 mg, 16%) as a white 
solid: IR (CHCl3) 3013, 2998, 2933, 1646, 1611, 1508, 1428, 
1231, 1157, 1068 cm−1; 1H NMR (270 MHz, CDCl3) δ7.88 (s, 
1H), 6.71 (s, 1H), 6.52 (s, 1H), 6.01 (s, 2H), 3.96 (s, 3H), 3.95 (s, 
3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H); 13C NMR (67.8 
MHz, CDCl3) δ 175.2, 154.7, 153.3, 151.6, 148.9, 142.8, 139.0, 
138.7, 136.9, 136.6, 121.4, 117.9, 113.1, 109.8, 101.7, 92.5, 60.3, 
56.9, 56.6, 56.4, 56.3; HRMS (ESI) m/z 439.0999, calcd for 
C21H20NaO9 [M+Na]+ 439.1000. 
 
4.1.14.  3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-7-hydroxy-
6-methoxy-4H-chromen-4-one (22) 
To a stirred solution of glaziovianin A analogue 20 (24.0 mg, 
52.6 mol) in CHCl3 (0.50 mL) and MeOH (0.10 mL) was added 
p-TsOH·H2O (1.1 mg, 5.79 mol) at room temperature. After the 
mixture was stirred at room temperature for 3 h, Et3N (0.01 mL) 
was added. Removal of solvent gave a solid, which was purified 
by column chromatography on silica gel (0.6 g, hexane–EtOAc = 
1:1 → 1:3) to give O7-demethyl analogue 22 (16.7 mg, 85%) as a 
white solid: IR (CHCl3) 3610, 3015, 2945, 1635, 1599, 1502, 
1461, 1288 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.89 (s, 1H), 
7.64 (s, 1H), 6.98 (s, 1H), 6.52 (s, 1H), 6.02 (s, 2H), 4.02 (s, 3H), 
3.87 (s, 3H), 3.85 (s, 3H), (OH proton was not observed); 13C 
NMR (67.8 MHz, CDCl3) δ 175.3, 153.8, 151.6, 151.8, 148.2, 
139.1, 138.8, 137.1, 136.6, 121.2, 118.5, 117.6, 109.7, 105.3, 
104.0, 102.0, 60.1, 56.9, 56.6; HRMS (ESI) m/z 395.0745, calcd 
for C19H16NaO8 [M+Na]+ 395.0737. 
 
4.1.15.  (3R,4S,5R)-2-(Acetoxymethyl)-6-(3-(4,7-
dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-
chromen-7-yloxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
(24) 
To a stirred solution of O7-demethyl analogue 22 (24.7 mg, 
66.4 mol) and MS3A (244 mg) in CH2Cl2 (0.50 mL) were 
added a solution of imidate 23 (65.1 mg, 133 mol) in CH2Cl2 
(0.50 mL) and BF3·Et2O (0.03 mL, 243 mol) at 0 °C. After 
being stirred at room temperature for 12 h, the mixture was 
diluted with water (2 mL) and extracted with CH2Cl2 (2 mL×3). 
The combined extracts were washed with brine (5 mL), dried 
(Na2SO4), and concentrated. The residual solid was purified by 
column chromatography on silica gel (0.7 g, hexane–EtOAc = 
4:1 → 2:1) to give tetraacetyl glycosylisoflavone 24 (mixture of 
anomeric isomers, -isomer: 1.9 mg, 4.1%; -isomer: 10.7 mg, 
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23%) as white solids: 24 (-isomer): IR (CHCl3) 3009, 2940, 
1672, 1667, 1646, 1522, 1434, 1245 cm−1; 1H NMR (270 MHz, 
pyridine-d5) δ 8.19 (s, 1H), 7.84 (s, 1H), 7.57 (s, 1H), 6.77 (s, 
1H), 5.99 (s, 2H), 5.92 (d, J = 8.4 Hz, 1H), 4.67–4.45 (m, 6H), 
4.00 (s, 3H), 3.80 (s, 3H), 3.70 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 
2.05 (s, 3H), 2.04 (s, 3H); 13C NMR (67.8 MHz, pyridine-d5) δ 
173.8, 170.9, 170.4, 169.8, 169.3, 157.8, 153.9, 151.8, 151.4, 
140.0, 138.9, 137.8, 136.7, 126.5, 120.7, 118.9, 109.4, 107.1, 
106.9, 103.4, 101.5, 72.9, 71.8, 71.3, 68.5, 64.2, 62.0, 58.4, 58.2, 
21.8, 21.3, 20.8, 20.5; HRMS (ESI) m/z 725.1694, calcd for 
C33H34NaO17 [M+Na]+ 725.1688. 
 
4.1.16. 3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-
7-((3R,4S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
2H-pyran-2-yloxy)-4H-chromen-4-one (25) 
To a stirred solution of tetraacetyl glycosylisoflavone 24 
(mixture of anomeric isomers, 4.5 mg, 6.41 mol) in MeOH 
(0.09 mL) was added NaOMe (3.5 mg, 69.4 mol) at 0 °C. After 
being stirred at room temperature for 1 h, the mixture was diluted 
with water (1 mL) and extracted with CHCl3 (1 mL×6). The 
combined extracts were dried (Na2SO4) and concentrated to give 
mixture of glycoside 25 (-isomer: 0.4 mg, 12%; -isomer 2.7mg, 
79%) as white solids: 25 (-isomer): IR (CHCl3) 3540, 3015, 
2944, 1646, 1530, 1456, 1435, 1246 cm−1; 1H NMR (270 MHz, 
pyridine-d5) δ 8.07 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 6.74 (s, 
1H), 5.99 (s, 2H), 5.89 (d, J = 7.0 Hz, 1H), 4.67–4.61 (m, 1H), 
4.44–4.26 (m, 5H), 3.99 (s, 3H), 3.79 (s, 3H), 3.63 (s, 3H), 
(Signals due to four protons (OH) were not observed); 13C NMR 
(67.8 MHz, pyridine-d5) δ 173.7, 157.5, 153.4, 150.7, 150.4, 
141.1, 139.3, 137.7, 136.6, 127.7, 120.9, 115.6, 109.2, 107.1, 
106.3, 103.5, 100.9, 74.8, 71.8, 71.4, 68.5, 64.4, 61.9, 58.4, 58.1; 
HRMS (ESI) m/z 557.1253, calcd for C25H26NaO13 [M+Na]+ 
557.1266. 
 
4.1.17.  7-(Allyloxy)-3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-
yl)-6-methoxy-4H-chromen-4-one (26) 
To a stirred solution of O7-demethyl analogue 22 (6.1 mg, 
16.4 μmol) in MeCN (0.16 mL) were added K2CO3 (4.5 mg, 32.6 
μmol) and allyl bromide (2.1 μL, 23.6 μmol) at room temperature. 
After being stirred at room temperature for 5 h, the mixture was 
diluted with saturated aqueous NaHCO3 (1 mL) and extracted 
with CH2Cl2 (2 mL×3). The combined extracts were washed with 
brine (2 mL), dried (Na2SO4), and concentrated. The residual 
solid was purified by column chromatography on silica gel (0.6 g, 
hexane–EtOAc = 5:1 → 3:1) to give allyl ether 26 (5.5 mg, 81%) 
as a white solid: IR (CHCl3) 3008, 2938, 1639, 1607, 1503, 1469, 
1430, 1267, 1099, 1063 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.89 
(s, 1H), 7.62 (s, 1H), 6.89 (s, 1H), 6.52 (s, 1H), 6.11 (ddt, J = 
17.6, 10.5, 5.4 Hz , 1H), 6.02 (s, 2H), 5.48 (ddt, J = 17.6, 1.4, 1.4 
Hz, 1H), 5.38 (ddt, J = 10.5, 1.4, 1.4 Hz, 1H), 4.72 (dt, J = 5.4, 
1.4 Hz, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H); 13C NMR 
(67.8 MHz, CDCl3) δ 175.2, 154.4, 153.4, 152.0, 147.8, 139.0, 
138.9, 137.0, 136.6, 135.8, 121.5, 118.0, 117.7, 116.5, 110.0, 
105.2, 101.8, 100.9, 73.3, 62.1, 57.0, 56.4; HRMS (ESI) m/z 
435.1057, calcd for C22H20NaO8 [M+Na]+ 435.1050. 
 
4.1.18.  7-(2,3-Dihydroxypropoxy)-3-(4,7-
dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4H-chromen-
4-one (27) 
To a stirred solution of allyl ether 26 (5.0 mg, 12.1 mol) in 
pyridine (0.12 mL) was added OsO4 (0.4 M solution in THF, 0.04 
mL, 16.0 mol) at room temperature. After being stirred at room 
temperature for 1.5 h, the reaction mixture was diluted with 
saturated aqueous NaHSO3 (1 mL), stirred at room temperature 
for 1 h, and extracted with CH2Cl2 (1 mL×3). The combined 
extracts were washed with brine (2 mL), dried (Na2SO4), and 
concentrated. The residual solid was purified by column 
chromatography on silica gel (0.6 g, hexane–EtOAc = 1:1 → 1:4) 
to give diol 27 (4.5 mg, 84%) as a white solid: IR (CHCl3) 3508, 
2968, 1637, 1608, 1505, 1458, 1267, 1101, 1060 cm−1; 1H NMR 
(270 MHz, CDCl3) δ 7.91 (s, 1H), 7.62 (s, 1H), 6.92 (s, 1H), 6.52 
(s, 1H), 6.03 (s, 2H), 4.28–4.19 (m, 5H), 3.96 (s, 3H), 3.87 (s, 
3H), 3.86 (s, 3H), (Signals due to two protons (OH) was not 
observed); 13C NMR (67.8 MHz, CDCl3) δ 175.3, 154.4, 153.4, 
151.8, 147.6, 139.1, 138.9, 137.0, 136.6, 135.8, 121.5, 118.0, 
117.7, 116.5, 110.0, 105.2, 101.8, 100.9, 73.3, 62.1, 57.0, 56.4; 
HRMS (ESI) m/z 435.1089, calcd for C22H22NaO10 [M+Na]+ 
469.1105. 
 
4.1.19.  7-(Benzyloxy)-3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-
yl)-6-methoxy-4H-chromen-4-one (28) 
To a stirred solution of O7-demethyl analogue 22 (6.8 mg, 
18.3 mol) in MeCN (0.18 mL) were added K2CO3 (5.2 mg, 37.7 
mol) and benzyl bromide (3.2 L, 26.9 mol). After being 
stirred at room temperature for 5 h, the mixture was diluted with 
saturated aqueous NaHCO3 (1 mL) and extracted with CH2Cl2 (2 
mL×3). The combined extracts were washed with brine (2 mL), 
dried (Na2SO4), and concentrated. The residual solid was purified 
by column chromatography on silica gel (0.6 g, hexane–EtOAc = 
5:1 → 3:1) to give benzyl ether 28 (6.8 mg, 80%) as a white 
solid: IR (CHCl3) 3007, 2939, 1606, 1470, 1298, 1227, 1153, 
1064 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.87 (s, 1H), 7.63 (s, 
1H), 7.49–7.19 (m, 5H), 6.90 (s, 1H), 6.51 (s, 1H), 6.02 (s, 1H), 
5.27 (s, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H); 13C NMR 
(67.8 MHz, CDCl3) δ 175.3, 153.3, 153.1, 151.9, 147.9, 139.0, 
138.9, 137.0, 136.7, 135.4, 128.7 (2C), 128.3, 127.2 (2C), 121.6, 
118.0, 117.9, 110.0, 105.1, 101.8, 101.3, 71.1, 60.2, 56.9, 56.4; 
HRMS (ESI) m/z 463.1379, calcd for C26H23O8 [M+H]+ 463.1387. 
 
4.1.20.  3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-
7-(prop-2-ynyloxy)-4H-chromen-4-one (29) 
To a stirred solution of O7-demethyl analogue 22 (6.1 mg, 
16.4 mol) in MeCN (0.16 mL) were added K2CO3 (4.5 mg, 32.6 mol) and propargyl bromide (2.1 L, 23.6 mol). After being 
stirred at room temperature for 5 h, the mixture was diluted with 
saturated aqueous NaHCO3 (1 mL) and extracted with CH2Cl2 (2 
mL×3). The combined extracts were washed with brine (2 mL), 
dried (Na2SO4), and concentrated. The residual solid was purified 
by column chromatography on silica gel (0.6 g, hexane–EtOAc = 
5:1 → 3:1) to give propargyl ether 29 (4.5 mg, 67%) as a white 
solid: IR (CHCl3) 3306, 3008, 2934, 1638, 1609, 1502, 1470, 
1431, 1398, 1267, 1231, 1209, 1099 cm−1; 1H NMR (270 MHz, 
CDCl3) δ 7.92 (s, 1H), 7.64 (s, 1H), 7.08 (s, 1H), 6.52 (s, 1H), 
6.03 (s, 2H), 4.90 (d, J = 2.2 Hz, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 
3.85 (s, 3H), 2.61 (s, 1H); 13C NMR (67.8 MHz, CDCl3) δ 175.2, 
153.5, 151.7, 147.8, 139.0, 138.9, 137.0, 136.7, 132.0, 121.7, 
118.5, 117.9, 110.0, 105.4, 101.8, 101.6, 84.1, 77.2, 60.2, 60.1, 
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56.9, 56.4; HRMS (ESI) m/z 411.1068, calcd for C22H18NaO8 
[M+H]+ 411.1074. 
 
4.1.21.  tert-Butyl 6-(6-
(benzyloxy)hexanamido)hexylcarbamate (32) 
To a stirred solution of 6-benzyloxyhexanoic acid 31 (97.3 mg, 
450 mol) in DMF (3.5 mL) were added HOBt (67.3 mg, 499 
mol) and DCC (103 mg, 500 mol) at 0 °C. After the mixture 
was stirred at 0 °C for 15 min, mono-Boc-1,6-diaminohexane 30 
(107 mg, 461 mol) was added at 0 °C. After being stirred at 
room temperature for 12 h, the mixture was filtered and 
concentrated. The crude product was diluted with EtOAc (10 
mL), washed with saturated aqueous NaHCO3 (5 mL), water (5 
mL), saturated aqueous NH4Cl (5 mL), and brine (5 mL). The 
combined extracts were dried (Na2SO4) and concentrated. The 
residual oil was purified by column chromatography on silica gel 
(3.0 g, CHCl3–MeOH = 1:0 → 20:1) to give amide 32 (153 mg, 
81%) as a white solid: IR (CHCl3) 3321, 3031, 2981, 1661, 1562, 
1559, 1243 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.37–7.26 (m, 
5H), 5.76 (br s, 1H), 4.61 (br s, 1H), 4.49 (s, 2H), 3.47 (t, J = 6.5 
Hz, 2H), 3.21 (dt, J = 6.8, 6.5 Hz, 2H), 3.09 (dt, J = 6.8, 6.5 Hz, 
2H), 2.16 (t, J = 7.3 Hz, 2H), 1.71–1.58 (m, 6H), 1.48–1.31 (m, 
8H), 1.44 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 172.9, 156.1, 
138.6, 128.3 (2C), 127.6 (2C), 127.5, 79.0, 72.9, 70.2, 40.2, 39.1, 
36.7, 33.9, 30.0, 29.5, 28.4 (3C), 26.2, 26.0, 25.6, 25.5; HRMS 
(ESI) m/z 443.2880, calcd for C24H40N2NaO4 [M+Na]+ 443.2880. 
 
4.1.22.  tert-Butyl 6-(6-hydroxyhexanamido)hexylcarbamate 
(32a) 
To a stirred solution of amide 32 (153 mg, 364 mol) in EtOH 
(4.0 mL) was added 5% Pd/C (50% water wet, 80.0 mg) at room 
temperature. After being stirred at room temperature for 12 h 
under H2, the mixture was filtered through a pad of Celite and 
concentrated. The residual solid was purified by column 
chromatography on silica gel (2.5 g, CHCl3–MeOH = 100:1 → 
20:1) to give alcohol 32a (107 mg, 89%) as a white solid: IR 
(CHCl3) 3342, 2975, 1655, 1558 cm−1; 1H NMR (270 MHz, 
CDCl3) δ 5.98 (br s, 1H), 4.67 (br s, 1H), 3.60 (t, J = 6.5 Hz, 2H), 
3.19 (q, J = 6.5 Hz, 2H), 3.07 (q, J = 6.5 Hz, 2H), 2.16 (t, J = 7.2 
Hz, 2H), 1.65 (quin, J = 7.2 Hz, 2H), 1.57 (quin, J = 6.5 Hz, 2H), 
1.50–1.41 (m, 6H), 1.44 (s, 9H), 1.37–1.29 (m, 4H), (A signal 
due to one proton (OH) was not observed); 13C NMR (125 MHz, 
CDCl3) δ 173.0, 156.1, 79.1, 62.5, 40.1, 39.1, 36.6, 32.2, 29.9, 
29.4, 28.4 (3C), 26.1, 26.0, 25.3, 25.1; HRMS (ESI) m/z 
353.2423, calcd for C17H34N2NaO4 [M+Na]+ 353.2411. 
 
4.1.23.  tert-Butyl 6-(6-bromohexanamido)hexylcarbamate 
(33) 
To a stirred solution of alcohol 32a (107 mg, 324 mol) in 
CH2Cl2 (3.2 mL) were added NBS (69.4 mg, 390 mol) and Ph3P 
(102 mg, 389 mol) at room temperature. After being stirred at 
room temperature for 14 h, the mixture was diluted with water (5 
mL) and extracted with CH2Cl2 (5 mL×3). The combined extracts 
were washed with brine (10 mL), dried (Na2SO4), and 
concentrated. The residual oil was purified by column 
chromatography on silica gel (5.0 g, CHCl3–MeOH = 100:1) to 
give bromide 33 (51.4 mg, 40%) as a white solid: IR (CHCl3) 
3327, 2970, 1649, 1553, 676 cm−1; 1H NMR (270 MHz, CDCl3) δ 
5.88 (br s, 1H), 4.61 (br s, 1H), 3.39 (t, J = 7.0 Hz, 2H), 3.21 (q, J 
= 6.5 Hz, 2H), 3.09 (q, J = 6.5 Hz, 2 H), 2.17 (t, J = 7.3 Hz, 2H), 
1.85 (quin, J = 7.0 Hz, 2H), 1.65 (quin, J = 7.3 Hz, 2H), 1.52–
1.29 (m, 10H), 1.43 (s, 9H); 13C NMR (67.8 MHz, CDCl3) δ 
171.8, 156.2, 79.4, 67.4, 40.5, 39.2, 36.6, 32.0, 29.7, 29.5, 28.9 
(3C), 27.5, 26.7, 26.0, 25.5; HRMS (ESI) m/z 415.1569 calcd for 
C17H33BrN2NaO3 [M+Na]+ 415.1567. 

4.1.24.  tert-Butyl 6-(6-(3-(4,7-dimethoxybenzo[d][1,3]dioxol-
5-yl)-6-methoxy-4-oxo-4H-chromen-7-
yloxy)hexanamido)hexylcarbamate (33a) 
To a stirred solution of O7-demethyl analogue 22 (6.9 mg, 
18.5 mol) and bromide 33 (21.1 mg, 53.8 mol) in CH2Cl2 
(0.27 mL) was added K2CO3 (7.4 mg, 53.6 mol) at 0 °C. After 
being stirred at reflux for 18 h, the mixture was diluted with 
water (1 mL) and extracted with CH2Cl2 (1 mL×3). The 
combined extracts were washed with brine (1 mL), dried 
(Na2SO4), and concentrated. The residual oil was purified by 
column chromatography on silica gel (0.6 g, hexane–EtOAc = 
1:4) to give coupling compound 33a (4.3 mg, 34%) as a white 
solid, and recovery of O7-demethyl analogue 22 (3.2 mg, 46%) as 
a white solid: IR (CHCl3) 3344, 3020, 2967, 1657, 1600, 1568, 
1502, 1288 cm−1; 1H NMR (270 MHz, CDCl3) δ 7.89 (s, 1H), 
7.60 (s, 1H), 6.86 (s, 1H), 6.52 (s, 1H), 6.02 (s, 2H), 5.64 (br s, 
1H), 4.55 (br s, 1H), 4.10 (t, J = 7.0 Hz, 2H), 3.96 (s, 3H), 3.87 (s, 
3H), 3.85 (s, 3H), 3.24 (q, J = 6.5 Hz, 2H), 3.10 (q, J = 6.5 Hz, 
2H), 2.22 (t, J = 7.3 Hz, 2H), 1.95 (quin, J = 7.0 Hz, 2H), 1.80–
1.70 (m, 2H), 1.57–1.23 (m, 10H), 1.44 (s, 9H); 13C NMR (67.8 
MHz, CDCl3) δ 175.3, 171.6, 156.2, 153.8, 151.8, 151.6, 148.2, 
139.1, 138.8, 137.1, 136.6, 121.2, 118.5, 117.6, 109.7, 105.3, 
104.0, 102.0, 79.4, 67.4, 60.1, 56.9, 56.6, 40.5, 39.2, 37.5, 36.9, 
36.6, 36.0, 32.0, 29.7, 29.5, 28.9 (3C), 25.5; HRMS (ESI) m/z 
707.3139, calcd for C36H48N2NaO11 [M+Na]+ 707.3150. 
 
4.1.25.  N-(6-Aminohexyl)-6-(3-(4,7-
dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-
chromen-7-yloxy)hexanamide (34) 
To a stirred solution of coupling compound 33a (4.3 mg, 6.29 
mol) in CH2Cl2 (0.10 mL) was added TFA (0.05 mL, 67.5 mol) at 0 °C. The mixture was stirred at room temperature for 4 
h and concentrated. The residual oil was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 20:1 → 
10:1) to give amine 34 (TFA salt; 2.7 mg, 62%) as a white solid: 
IR (CHCl3) 3326, 3024, 2980, 1648, 1591, 1554, 1510, 1285 
cm−1; 1H NMR (270 MHz, CDCl3) δ 7.89 (s, 1H), 7.57 (s, 1H), 
6.85 (s, 1H), 6.50 (s, 1H), 6.20 (br s, 1H), 6.01 (s, 2H), 4.09 (t, J 
= 5.9 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H), 3.20–3.13 
(m, 2H), 2.96–2.90 (m, 2H), 2.20 (t, J = 7.3 Hz, 2H), 1.95–1.89 
(m, 2H), 1.74–1.25 (m, 12H), (Signals due to two protons (NH) 
were not observed); 13C NMR (67.8 MHz, CDCl3) δ 175.2, 171.6, 
153.8, 151.8, 151.6, 148.2, 139.1, 138.8, 137.1, 136.6, 121.2, 
118.5, 117.6, 109.7, 105.3, 104.0, 102.0, 67.4, 60.1, 56.9, 56.6, 
40.5, 39.2, 37.5, 36.7, 36.6, 36.0, 32.0, 29.7, 29.5, 25.5; HRMS 
(ESI) m/z 607.2638, calcd for C31H40N2NaO9 [M+Na]+ 607.2626. 
 
4.1.26.  6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-
methoxy-4-oxo-4H-chromen-7-yloxy)-N-(6-(5-((3aS,4S,6aR)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexyl)hexanamide (36) 
To a stirred solution of amine 34 (2.7 mg, 3.87 mol) and (+)-
biotin N-hydroxysuccinimide ester 35 (2.0 mg, 5.87 mol) in 
DMF (0.08 mL) was added Et3N (3.0 L, 21.6 mol) at room 
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temperature. After being stirred at room temperature for 14 h, the 
mixture was diluted with brine (0.5 mL) and extracted with 
CH2Cl2 (1 mL×3). The combined extracts were dried (Na2SO4) 
and concentrated. The residual oil was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 50:1 → 
20:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and 
JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, 
UV 265 nm; solvent CHCl3] to give O7-biotinyl glaziovianin A 
(36) (2.7 mg, 41%) as a white solid: IR (CHCl3) 3340, 3031, 
2974, 1719, 1643, 1562, 1510, 1286, 1202 cm−1; 1H NMR (270 
MHz, CDCl3) δ 7.90 (s, 1H), 7.56 (s, 1H), 6.85 (s, 1H), 6.52 (s, 
1H), 6.31 (br s, 1H), 6.16 (br s, 1H), 6.00 (s, 2H), 5.27 (s, 1H), 
5.02 (s, 1H), 4.60–4.53 (m, 1H), 4.39–4.31 (m, 1H), 4.10 (t, J = 
5.9 Hz, 2H), 3.95 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.25–3.09 
(m, 5H), 2.94–2.89 (m, 2H), 2.31 (t, J = 7.3 Hz, 2H), 2.22 (t, J = 
7.3 Hz, 2H), 1.84–1.33 (m, 20H); 13C NMR (125 MHz, CDCl3) δ 
178.8, 175.3, 171.4, 170.0, 153.8, 151.8, 151.5, 148.1, 139.1, 
138.6, 137.0, 136.8, 121.2, 118.4, 117.5, 109.7, 105.3, 103.9, 
102.1, 67.4, 60.0, 56.9, 56.7, 55.6, 53.9, 45.4, 40.7, 40.5, 39.1, 
37.5, 37.0, 36.4, 35.9, 35.5, 32.3, 29.8, 29.5, 27.8, 26.7, 26.4, 
25.5; HRMS (ESI) m/z 833.3385, calcd for C41H54N4NaO11S 
[M+Na]+ 833.3402. 

4.1.27.  (E)-Methyl 6-hydroxyhex-4-enoate (38) 
To a stirred solution of aldehyde 37 (535 mg, 3.77 mmol) in 
MeOH (15 mL) was added NaBH4 (171 mg, 4.52 mmol) at 0 °C. 
After being stirred at 0 °C for 1 h, the mixture was diluted with 
saturated aqueous NH4Cl (8 mL) and water (30 mL) and 
extracted with CH2Cl2 (20 mL×3). The combined extracts were 
dried (Na2SO4) and concentrated. The residual oil was purified by 
column chromatography on silica gel (12 g, EtOAc–hexane = 
3:1) to give allylic alcohol 38 (380 mg, 70%) as a white solid: IR 
(CHCl3) 3340, 2986, 1739, 1670 cm−1; 1H NMR (270 MHz, 
CDCl3) δ 5.71–5.68 (m, 2H), 4.34 (dt, J = 5.4, 1.6 Hz, 2H), 3.68 
(s, 3H), 2.38 (t, J = 7.6 Hz, 2H), 2.18 (dt, J = 7.6, 5.1 Hz, 2H), (A 
signal due to one proton (OH) was not observed); 13C NMR (125 
MHz, CDCl3) δ 173.1, 132.5, 129.6, 74.2, 53.0, 33.5, 29.9; 
HRMS (ESI) m/z 167.0698, calcd for C7H12NaO3 [M+Na]+ 
167.0679. 
 
4.1.28.  (E)-Methyl 6-(tert-butyldimethylsilyloxy)hex-4-enoate 
(39) 
To a stirred solution of allylic alcohol 38 (370 mg, 2.57 mmol) 
in DMF (26 mL) were added imidazole (385 mg, 5.65 mmol) and 
TBSCl (427 mg, 2.83 mmol) at room temperature. After being 
stirred at room temperature for 2 h, the mixture was diluted with 
water (10 mL) and extracted with EtOAc (15 mL×3). The 
combined extracts were washed with brine (10 mL), dried 
(Na2SO4), and concentrated. The residual oil was purified by 
column chromatography on silica gel (17 g, EtOAc–hexane = 
30:1 → 10:1) to give TBS ether 39 (603 mg, 91%) as a white 
solid: IR (CHCl3) 2978, 1743, 1661 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 5.72–5.64 (m, 2H), 4.21 (dt, J = 6.0, 1.4 Hz, 2H), 3.60 
(s, 3H), 2.30 (t, J = 7.6 Hz, 2H), 2.16 (dt, J = 7.6, 5.2 Hz, 2H), 
0.89 (s, 9H), 0.07 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 173.2, 
131.9, 128.5, 74.4, 53.2, 33.0, 29.6, 25.2 (3C), 18.4, –4.8 (2C); 
HRMS (ESI) m/z 281.1537, calcd for C13H26NaO3Si [M+Na]+ 
281.1543. 
 
4.1.29.  (E)-tert-Butyl 6-(6-(tert-butyldimethylsilyloxy)hex-4-
enamido)hexylcarbamate (40) 
To a stirred solution of TBS compound 39 (314 mg, 1.22 
mmol) in toluene (4.1 mL) was added amine 30 (394 mg, 1.82 
mmol) at room temperature. After being stirred at reflux for 24 h, 
the mixture was cooled to room temperature, diluted with water 
(5 mL), and extracted with CH2Cl2 (5 mL×3). The combined 
extracts were washed with brine (5 mL), dried (Na2SO4), and 
concentrated. The residual oil was purified by column 
chromatography on silica gel (18 g, CHCl3–MeOH = 1:0 → 
100:1) to give amide 40 (371 mg, 69%) as a white solid: IR 
(CHCl3) 3375, 2968, 1661, 1652, 1568 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 5.92 (br s, 1H), 5.75–5.65 (m, 2H), 4.88 (br s, 1H), 4.21 
(dt, J = 6.3, 1.5 Hz, 2H), 3.27 (q, J = 6.0 Hz, 2H), 3.16 (q, J = 6.0 
Hz, 2H), 2.22 (t, J = 7.8 Hz, 2H), 2.16 (dt, J = 7.8, 5.8 Hz, 2H), 
1.51–1.46 (m, 4H), 1.40 (s, 9H), 1.34–1.30 (m, 4H), 0.89 (s, 9H), 
0.07 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 173.7, 157.0, 132.0, 
128.5, 78.6, 74.6, 41.1, 40.2, 34.0, 29.9, 29.3, 29.1, 28.3 (3C), 
25.7, 25.5, 25.2 (3C), 18.4, –4.8 (2C); HRMS (ESI) m/z 465.3117, 
calcd for C23H46N2NaO4Si [M+Na]+ 465.3119. 
 
4.1.30.  (E)-tert-Butyl 6-(6-hydroxyhex-4-
enamido)hexylcarbamate (41) 
To a stirred solution of TBS ether 40 (360 mg, 814 mol) in 
THF (8.1 mL) was added TBAF (276 mg, 1.06 mmol) at room 
temperature. After being stirred at room temperature for 4 h, the 
mixture was diluted with saturated NH4Cl (7 mL) and extracted 
with CH2Cl2 (8 mL×3). The combined extracts were washed with 
brine (10 mL), dried (Na2SO4), and concentrated. The residual oil 
was purified by column chromatography on silica gel (10 g, 
CHCl3–MeOH = 50:1 → 20:1) to give allylic alcohol 41 (230 mg, 
86%) as a white solid: IR (CHCl3) 3362, 2972, 1669, 1649, 1551 
cm−1; 1H NMR (500 MHz, CDCl3) δ 5.81–5.70 (m, 3H), 4.79 (br 
s, 1H), 4.25 (dt, J = 5.2, 1.9 Hz, 2H), 3.27 (q, J = 6.0 Hz, 2H), 
3.19 (q, J = 6.0 Hz, 2H), 2.20 (t, J = 7.5 Hz, 2H), 2.15 (dt, J = 7.5, 
5.4 Hz, 2H), 1.51–1.47 (m, 4H), 1.43 (s, 9H), 1.36–1.30 (m, 4H), 
(A signal due to one proton (OH) was not observed); 13C NMR 
(125 MHz, CDCl3) δ 173.5, 156.9, 132.3, 128.5, 78.4, 74.6, 41.1, 
40.0, 33.7, 29.6, 29.3, 29.0, 28.2 (3C), 25.9, 25.6; HRMS (ESI) 
m/z 351.2281, calcd for C17H32N2NaO4 [M+Na]+ 351.2254. 
 
4.1.31.  (E)-tert-Butyl 6-(6-bromohex-4-
enamido)hexylcarbamate (42) 
To a stirred solution of allylic alcohol 41 (222 mg, 677 mol) 
in CH2Cl2 (6.8 mL) were added Ph3P (213 mg, 813 mol) and 
NBS (145 mg, 815 mol) at room temperature. After being 
stirred at room temperature for 13 h, the mixture was diluted with 
water (5 mL) and extracted with CH2Cl2 (7 mL×3). The 
combined extracts were washed with brine (10 mL), dried 
(Na2SO4), and concentrated. The residual oil was purified by 
column chromatography on silica gel (13 g, CHCl3–MeOH = 1:0 → 100:1) to give allylic bromide 42 (169 mg, 64%) as a white 
solid: IR (CHCl3) 3368, 2976, 1660, 1642, 1539, 691 cm−1; 1H 
NMR (500 MHz, CDCl3) δ 5.82 (br s, 1H), 5.69–5.65 (m, 2H), 
4.69 (br s, 1H), 4.03 (dt, J = 5.7, 1.6 Hz, 2H), 3.26 (q, J = 5.9 Hz, 
2H), 3.20 (q, J = 5.6 Hz, 2H), 2.20 (t, J = 7.7 Hz, 2H), 2.12 (dt, J 
= 7.7, 5.5 Hz, 2H), 1.55–1.48 (m, 4H), 1.45 (s, 9H), 1.37–1.29 (m, 
4H); 13C NMR (125 MHz, CDCl3) δ 173.6, 157.1, 129.7, 126.9, 
78.5, 69.2, 41.1, 40.6, 33.8, 29.5, 29.1, 28.7, 28.2 (3C), 26.0, 
25.5; HRMS (ESI) m/z 413.1404, calcd for C17H31BrN2NaO3 
[M+Na]+ 413.1410. 
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 4.1.32.  (E)-tert-Butyl 6-(6-(3-(4,7-
dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-
chromen-7-yloxy)hex-4-enamido)hexylcarbamate (43) 
To a stirred solution of O7-demethyl analogue 22 (10.3 mg, 
27.7 mol) and allylic bromide 42 (19.2 mg, 58.5 mol) in 
MeCN (0.28 mL) was added K2CO3 (9.4 mg, 68.1 mol) at room 
temperature. After being stirred at reflux for 13 h, the mixture 
was cooled to room temperature, diluted with saturated NH4Cl 
(0.5 mL), and extracted with CH2Cl2 (1 mL×3). The combined 
extracts were washed with brine (2 mL), dried (Na2SO4), and 
concentrated. The residual oil was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 400:1 → 
100:1) to give coupling compound 43 (11.0 mg, 72%) as a white 
solid, and recovery of phenol 22 (1.4 mg, 14%) as a white solid: 
IR (CHCl3) 3356, 3024, 2985, 1676, 1660, 1611, 1575, 1499, 
1282 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.60 (s, 
1H), 6.85 (s, 1H), 6.52 (s, 1H), 6.00 (s, 2H), 5.86–5.80 (m, 3H), 
4.62 (br s, 1H), 4.48 (dt, J = 7.0, 1.8 Hz, 2H), 3.96 (s, 3H), 3.87 
(s, 3H), 3.85 (s, 3H), 3.27 (q, J = 6.3 Hz, 2H), 3.19 (q, J = 6.3 Hz, 
2H), 2.25 (t, J = 7.3 Hz, 2H), 2.02 (dt, J = 7.3, 5.2 Hz, 2H), 1.58–
1.50 (m, 4H), 1.44 (s, 9H), 1.35–1.29 (m, 4H); 13C NMR (125 
MHz, CDCl3) δ 175.5, 171.4, 156.4, 153.8, 151.8, 151.2, 147.7, 
138.9, 138.7, 137.1, 136.5, 136.3, 132.5, 121.2, 118.4, 117.1, 
109.5, 105.0, 104.0, 102.2, 79.6, 77.6, 60.0, 56.9, 56.7, 39.8, 39.2, 
36.9, 36.0, 31.8, 31.4, 29.4, 28.7 (3C), 25.3; HRMS (ESI) m/z 
705.2996, calcd for C36H46N2NaO11 [M+Na]+ 705.2994. 
 
4.1.33.  (E)-N-(6-Aminohexyl)-6-(3-(4,7-
dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-
chromen-7-yloxy)hex-4-enamide (44) 
To a stirred solution of coupling compound 43 (8.0 mg, 11.7 
mol) in CH2Cl2 (0.20 mL) was added TFA (0.010 mL, 135 
mol) at 0 °C. The mixture was stirred at room temperature for 3 
h and concentrated. The residual solid was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 20:1 → 
10:1) to give amine 44 (TFA salt; 4.4 mg, 55%) as a white solid: 
IR (CHCl3) 3339, 3030, 2978, 1672, 1654, 1607, 1562, 1510, 
1293 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.61 (s, 
1H), 6.85 (s, 1H), 6.55 (s, 1H), 6.13 (br s, 1H), 6.01 (s, 2H), 
5.82–5.76 (m, 2H), 4.47 (dt, J = 7.2, 1.6 Hz, 2H), 3.95 (s, 3H), 
3.87 (s, 3H), 3.84 (s, 3H), 3.27–3.21 (m, 2H), 2.95–2.90 (m, 2H), 
2.29 (t, J = 7.4 Hz, 2H), 2.07 (dt, J = 7.4, 5.4 Hz, 2H), 1.63–1.55 
(m, 4H), 1.36–1.30 (m, 4H), (Signals due to two protons (NH) 
were not observed); 13C NMR (125 MHz, CDCl3) δ 175.8, 171.4, 
153.8, 152.1, 151.5, 147.3, 138.9, 138.7, 137.1, 136.4, 136.1, 
132.7, 121.1, 118.2, 117.1, 109.5, 105.0, 104.0, 102.0, 77.5, 60.3, 
56.9, 56.5, 40.1, 39.4, 36.6, 35.8, 31.7, 31.4, 29.4, 25.2; HRMS 
(ESI) m/z 605.2480, calcd for C31H38N2NaO9 [M+Na]+ 605.2470. 
 
4.1.34.  (E)-6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-
methoxy-4-oxo-4H-chromen-7-yloxy)-N-(6-(5-((3aS,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexyl)hex-4-enamide (45) 
To a stirred solution of amine 44 (2.8 mg, 4.02 mol) and (+)-
biotin N-hydroxysuccinimide ester 35 (2.1 mg, 6.16 mol) in 
DMF (0.08 mL) was added Et3N (2.8 L, 20.2 mol) at room 
temperature. After being stirred at room temperature for 16 h, the 
mixture was diluted with brine (0.5 mL) and extracted with 
CH2Cl2 (1 mL×3). The combined extracts were dried (Na2SO4) 
and concentrated. The residual oil was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 50:1 → 
20:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and 
JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, 
UV 265 nm; solvent CHCl3] to give O7-modified biotin probe 45 
(1.5 mg, 47%) as a white solid: IR (CHCl3) 3350, 3020, 2982, 
1723, 1673, 1650, 1607, 1574, 1286, 1199 cm−1; 1H NMR (500 
MHz, CDCl3) δ 7.90 (s, 1H), 7.60 (s, 1H), 6.82 (s, 1H), 6.56 (s, 
1H), 6.15 (br s, 1H), 6.04 (br s, 1H), 6.02 (s, 2H), 5.81–5.76 (m, 
2H), 5.23 (s, 1H), 4.97 (s, 1H), 4.62–4.57 (m, 1H), 4.44 (dt, J = 
7.0, 1.5 Hz, 2H), 4.36–4.32 (m, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 
3.85 (s, 3H), 3.27–3.13 (m, 5H), 2.93–2.88 (m, 2H), 2.33 (t, J = 
7.2 Hz, 2H), 2.24 (t, J = 7.6 Hz, 2H), 2.07 (dt, J = 7.6, 5.2 Hz, 
2H), 1.87–1.70 (m, 4H), 1.65–1.50 (m, 6H), 1.35–1.29 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ 179.0, 175.8, 171.2, 169.7, 154.0, 
152.1, 151.5, 147.5, 139.0, 138.8, 137.1, 136.1, 135.7, 132.8, 
121.0, 118.4, 117.1, 109.5, 105.4, 104.1, 101.8, 77.9, 60.1, 56.9, 
56.6, 55.4, 54.0, 45.4, 40.5, 39.4, 37.2, 36.6, 35.8, 35.3, 32.0, 
31.4, 29.6, 27.7, 26.7, 26.1, 25.5; HRMS (ESI) m/z 831.3241, 
calcd for C41H52N4NaO11S [M+Na]+ 831.3245. 
 
4.1.35.  (E)-N-(6-(6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-
yl)-6-methoxy-4-oxo-4H-chromen-7-yloxy)hex-4-
enamido)hexyl)-4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzamide (46) 
To a stirred solution of amine 44 (2.1 mg, 3.02 mol) and 3-
trifluoromethyl-3-phenyldiazirine succinimide ester 48 (1.5 mg, 
4.59 mol) in MeCN (0.06 mL) was added Et3N (2.0 L, 14.4 
mol) at room temperature. After being stirred at room 
temperature for 24 h, the mixture was diluted with brine (0.5 mL) 
and extracted with CH2Cl2 (1 mL×3). The combined extracts 
were dried (Na2SO4) and concentrated. The residual oil was 
purified by column chromatography on silica gel (0.6 g, CHCl3–
MeOH = 300:1 → 100:1) to give O7-modified photoaffinity 
probe 46 (1.2 mg, 49%) as a white solid: IR (CHCl3) 3345, 3028, 
2980, 1672, 1658, 1602, 1578, 1559, 1514, 1288 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 7.98 (d, J = 8.0 Hz, 2H), 7.89 (s, 1H), 7.63 
(s, 1H), 7.19 (d, J = 8.0 Hz, 2H), 6.86 (s, 1H), 6.51 (s, 1H), 6.30 
(br s, 1H), 6.13 (br s, 1H), 6.02 (s, 2H), 5.85–5.79 (m, 2H), 4.47 
(dt, J = 7.0, 1.8 Hz, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H), 
3.37–3.25 (m, 4H), 2.26 (t, J = 7.5 Hz, 2H), 2.05 (dt, J = 7.5, 5.0 
Hz, 2H), 1.64–1.55 (m, 4H), 1.38–1.30 (m, 4H); 13C NMR (125 
MHz, CDCl3) δ 176.0, 172.4, 171.1, 153.8, 152.5, 151.7, 147.3, 
139.0, 138.6, 137.2, 136.4, 135.9, 134.8, 132.7, 130.2 (2C), 130.0, 
126.7 (2C), 122.9 (q, 1JC,F = 275 Hz), 121.1, 118.4, 117.2, 109.7, 
104.9, 104.1, 102.0, 77.2, 60.3, 57.0, 56.6, 39.6, 39.3, 36.5, 35.9, 
31.7, 31.4, 29.5, 28.4 (q, 2JC,F = 50.0 Hz), 25.2; HRMS (ESI) m/z 
817.2675, calcd for C40H41F3N4NaO10 [M+Na]+ 817.2667. 
 
4.1.36.  (E)-10-(4-(6-(6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-
5-yl)-6-methoxy-4-oxo-4H-chromen-7-yloxy)hex-4-
enamido)hexylamino)-4-oxobutyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-dipyrrolo[1,2-c:1',2'-f][1,3,2]diazaborinin-4-
ium-5-uide (47) 
To a stirred solution of amine 44 (1.4 mg, 2.05 mol) and 
BODIPY succinimide ester 49 (1.4 mg, 3.25 mol) in MeCN 
(0.05 mL) was added Et3N (1.5 L, 10.8 mol) at room 
temperature. After being stirred at room temperature for 24 h, the 
mixture was diluted with brine (0.5 mL) and extracted with 
CH2Cl2 (1 mL×3). The combined extracts were dried (Na2SO4) 
and concentrated. The residual oil was purified by column 
chromatography on silica gel (0.6 g, CHCl3–MeOH = 100:1 → 
40:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and 
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JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, 
UV 265 nm; solvent CHCl3] to give O7-modified fluorescent 
probe 47 (1.2 mg, 65%) as a white solid: IR (CHCl3) 3358, 3025, 
3019, 2982, 2850, 1665, 1653, 1607, 1555, 1294 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 7.90 (s, 1H), 7.61 (s, 1H), 6.84 (s, 1H), 6.55 
(s, 1H), 6.22 (br s, 1H), 6.11 (br s, 1H), 6.06 (s, 2H), 6.02 (s, 2H), 
5.80–5.74 (m, 2H), 4.45 (dt, J = 7.2, 1.6 Hz, 2H), 3.96 (s, 3H), 
3.86 (s, 3H), 3.84 (s, 3H), 3.28–3.20 (m, 4H), 3.05 (t, J = 8.4 Hz, 
2H), 2.52 (s, 6H), 2.45 (s, 6H), 2.41 (t, J = 7.0 Hz, 2H), 2.28 (t, J 
= 7.4 Hz, 2H), 2.05–1.98 (m, 4H), 1.65–1.59 (m, 4H), 1.36–1.29 
(m, 4H); 13C NMR (125 MHz, CDCl3) δ 175.8, 173.9, 171.7, 
154.3, 153.9, 152.0, 151.2, 147.3, 144.7 (2C), 140.4 (2C), 139.1, 
138.7, 137.4, 136.4, 136.0, 132.6, 131.5 (2C), 121.9 (2C), 120.9, 
118.2, 117.1, 109.4, 105.1, 104.3, 101.8, 77.8, 60.0, 56.8, 56.5, 
40.1, 39.5, 36.4, 35.8, 31.5, 31.2, 30.5, 29.4, 27.4, 26.5, 25.1, 
16.3 (2C), 14,4 (2C); HRMS (ESI) m/z 921.4025, calcd for 
C48H57BF2N4NaO10 [M+Na]+ 921.4028. 
 
4.2. Bioassay 
Cell survival was determined by a WST-8 assay kit (Dojindo 
Laboratories, Kumamoto, Japan). HeLa S3 cells (3×103 
cells/well) in 96 well plates were incubated overnight. Then, cells 
were treated with various concentrations of each compound. 
After 48 h incubation, 10 µL of WST-8 reagents were added to 
the culture. After 2 h incubation, the absorbance at 450 nm was 
measured with iMark microplate reader (BioRad Laboratories, 
Inc). Absorbance correlates with the number of living cells. The 
number of living cells (% control) was calculated with the 
following formula: (each absorbance - absorbance of blank well) 
/ (absorbance of 0 µM well - absorbance of blank well) × 100. 
 
4.3. Cell culture and reagents 
Human cervix epidermoid carcinoma HeLa S3 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal-calf serum (FCS, Cell Culture Bioscience). 
Cells were grown at 37 ºC in a 5% CO2 atmosphere. Antibodies 
specific for α-tubulin (DM1A, #sc-32293) was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Alexa488-
conjugated anti-mouse IgG antibody (#A11001) was purchased 
from Invitrogen. DAPI solution was purchased from Wako Pure 
Chemical Industry (Osaka, Japan). 
 
4.3.1. Analysis of cell cycle progression 
3×104 cells/mL HeLa S3 cells were treated with various 
concentrations of each compound for 24 h, then harvested and 
fixed with 70% EtOH (–20 ºC). After staining with propidium 
iodide solution, DNA contents were measured by flow 
cytometric analysis (Attune® Acoustic Focusing Cytometer; 
Applied Biosystems). 
 
4.3.2. Immunofluorescence procedures 
3×104 cells/mL HeLa S3 cells were seeded on sterile coverslips. 
After treatment of each compound for 6 h, coverslips were fixed 
with –20 ºC MeOH for 5 min. After being washed with PBS-B 
(PBS containing 0.5% (w/v) BSA), coverslips were overlaid with 
anti-α-tubulin antibody in PBS-B then placed in a humidified 
container at 37 ºC and incubated for 1 h. After being washed 
twice with PBS-B, coverslips were overlaid with Alexa488-
conjugated anti-mouse IgG antibody in PBS-B, incubated for 1 h, 
washed with PBS and mounted with 0.1 g/mL DAPI solution. 
The morphology of microtubule and nuclei were observed under 
a Leica LAS AF 6000 fluorescent microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). Dilutions of 
antibodies were 1:250 (antibodies specific for α-tubulin) and 
1:2000 (Alexa488-conjugated anti-mouce IgG antibody). 
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